Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

New drug blocks common cancer pathway

Scientists have developed a new drug which can reduce the growth of tumours in mice by up to 98 per cent, according to a study published in Molecular Cancer Therapeutics ** this week.

15 Jul 2009

Two reproductive factors are important predictors of death from ovarian cancer

Researchers from the Centers for Disease Control and Prevention (CDC) found that survival among women with ovarian cancer is influenced by age of menarche and total number of lifetime ovulatory cycles.

9 Jul 2009

Blacks with equal care still more likely to die of some cancers

"African Americans are less likely than whites to survive breast, prostate and ovarian cancer even when they receive equal treatment, according to a large study that offers provocative evidence that biological factors play a role in at least some racial disparities," the Washington Post reports.

8 Jul 2009

Research leads to advanced trials of new cancer treatment

Prof. Hochberg was successful in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer, including superficial bladder carcinoma and pancreatic, ovarian and metastatic liver cancer, while laying dormant and non-expressed in non-cancerous cells.

15 Jun 2009

Discovery of new angiogenesis protein - possible cancer drug target

To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.

9 Jun 2009

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.

9 Jun 2009

Protein abundant in embryonic stem cells offers a new cancer target

A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston.

1 Jun 2009

Genetic testing for breast or ovarian cancer risk may be greatly underutilized

Although a test for gene mutations known to significantly increase the risk of hereditary breast or ovarian cancer has been available for more than a decade, a new study finds that few women with family histories of these cancers are even discussing genetic testing with their physicians or other health care providers.

22 May 2009

Genetic marker predicts earlier onset of prostate cancer in Caucasian men

Fox Chase Cancer Center researchers have identified a genetic marker that is associated with an earlier onset of prostate cancer in Caucasian men who have a family history of prostate cancer. If the data are confirmed, the marker may help clinicians personalize prostate cancer screening.

17 May 2009

American Civil Liberties Union challenges breast cancer gene patents

The American Civil Liberties Union and the Public Patent Foundation at Benjamin N. Cardozo School of Law (PUBPAT) filed a lawsuit today charging that patents on two human genes associated with breast and ovarian cancer stifle research that could lead to cures and limit women's options regarding their medical care.

12 May 2009

Scientists discover pattern of genetic faults to predict cancer drug success

A pattern of genetic defects in tumours could indicate whether ovarian cancer patients will respond to common chemotherapy drugs before treatment starts, reveals a Cancer Research UK study published in the Proceedings of the National Academy of Sciences today (Monday).

4 May 2009

New MR procedure may help save women from unnecessary breast biopsies

A new MR procedure that uses diffusion-weighted imaging (DWI) to determine whether or not a breast lesion is malignant or benign may help reduce unnecessary breast biopsies, according to a study performed at the National Institute of Health in Bethesda, MD.

23 Apr 2009

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics, Inc. has announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-targeted agents. In addition, data with SGN-75 indicate its therapeutic potential in multiple types of solid tumors.

22 Apr 2009

Removal of ovaries during hysterectomy increases risk of death, outweighs benefits

Results of a landmark study led by a doctor at John Wayne Cancer Institute at Saint John's Health Center raises serious questions about the long-term survival benefits of removing a woman's ovaries during routine hysterectomy.

20 Apr 2009

Overexpression of PEA-15 protein shrinks breast cancer tumors

Overexpression of PEA-15, which binds and drags an oncoprotein out of the cell nucleus where it fuels cancer growth, steeply reduced breast cancer tumors in a preclinical experiment, researchers at The University of Texas M. D. Anderson Cancer Center reported at the 100th annual meeting of the American Association for Cancer Research.

20 Apr 2009

Molecular profiling helps cancer patients survive

Cancer patients can survive longer under treatments based on their individual genetic profiles, according to a nationwide study released jointly today by Phoenix-area healthcare organizations.

20 Apr 2009

Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers

The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.

20 Apr 2009